AZAjayrajsinh R. Zala

Ajayrajsinh R. Zala

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ajayrajsinh R. Zala has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Exploring the Antimycobacterial Potential of Purine‐Piperazine Hybrids via in Vitro and in Silico Approaches

    by Khushal J. Vekariya, Gautam P. Savaliya, Sabirkhan Pathan, Mohit Agrawal, Mohd Imran, Ajayrajsinh R. Zala

    Novel purine‐based piperazine analogs were rationally designed and synthesized using fluoro‐substituted benzoyl chloride as a key intermediate. The synthesized compounds were characterized and evaluated for their potential anti‐tubercular activity. In vitro biological screening revealed that compounds S1C , S1D , and S1F exhibited significant antimycobacterial activity, with MIC values ranging from 8.5 to 18.8 µg/mL. To gain molecular insights into their mechanism of action, molecular docking studies were performed against UDP‐N‐acetylenolpyruvoylglucosamine reductase (MurB) from Mycobacterium tuberculosis. The docking results demonstrated favorable binding affinities, characterised by key hydrogen bonding and hydrophobic interactions at the active site. Additionally, 100 ns molecular dynamics simulations were conducted to assess the stability of the protein–ligand complexes. ADME profiles were predicted using the PreADME server, suggesting acceptable pharmacokinetic and pharmacodynamic properties. Overall, the biological evaluation, computational modeling, and favorable ADME profiles indicate that compounds S1C , S1D , and S1F are potential candidates for anti‐tubercular drug development.


  • Versatile Therapeutic Values of N‐Containing Heterocycles Benzimidazole, Piperazine and Piperidine Hybrids

    by Ajayrajsinh R. Zala, Premlata Kumari

    Nitrogen‐containing benzimidazole, piperazine, and piperidine are significant pharmacophores in medicinal chemistry and drug development. Many medications, lead compounds, and various reagents have these N‐containing scaffolds. This review concentrated on the development of novel therapeutic agents as well as the broad range of pharmacological actions demonstrated by benzimidazole, piperazine, and piperidine hybrids. The review emphasizes these hybrids′ potential, range, and medical significance. The review also discusses the structural criteria for benzimidazole, piperazine, and piperidine hybrids created by diverse chemists to be physiologically effective against a variety of disorders.


  • Synthesis, characterization, molecular dynamic simulation, and biological assessment of cinnamates linked to imidazole/benzimidazole as a CYP51 inhibitor

    by Ajayrajsinh R. Zala, Dhanji P. Rajani, Iqrar Ahmad, Harun Patel, Premlata Kumari

    A class of 2-(1H-imidazol-1-yl)-1-phenylethyl cinnamates 6a-6j and 2-(1H-benzo[d]imidazol-1-yl)-1-phenylethyl cinnamates 7a-7j were synthesized, and their synthesis was validated using various spectroscopic techniques like IR, NMR, and Mass spectrometry. In addition, the compounds were assessed for in-vitro antibacterial against gram-positive and gram-negative strains and in-vitro antifungal against six different fungal strains. Compounds 6 g, 7 b, 7f, and 7 g exhibited significant activity against all bacterial strains ranging from MIC = 12.5-50 µg/mL, and compounds 6 g, 7 b, and 7 g exhibited considerable activity against all fungal strains ranging from MFC = 125-200 µg/mL. A molecular docking study indicated that compounds 6 g, 7 b, 7 g, and 7j could be lodged in the active pocket and inhibit C. albicans Sterol 14α-demethylase (CYP51) protein via various interactions, and these studies validate the antifungal results. Different parameters from the 100 ns MD simulation study are investigated to evaluate the dynamic stability of protein-ligand complexes. According to the MD simulation study, the proposed compounds effectively kept their molecular interaction and structural integrity within the C. albicans Sterol 14-demethylase. Compounds 6 g, 7 b, and 7 g are promising lead compounds in searching for novel antifungal drug-like molecules. Furthermore, in silico ADME indicates that these compounds possess drug-like physicochemical properties to be orally bioavailable. Communicated by Ramaswamy H. Sarma